140,631 Shares in uniQure (NASDAQ:QURE) Purchased by Woodline Partners LP

Woodline Partners LP acquired a new stake in uniQure (NASDAQ:QURE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 140,631 shares of the biotechnology company's stock, valued at approximately $2,484,000. Woodline Partners LP owned 0.29% of uniQure at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its stake in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after buying an additional 969 shares during the period. Tudor Investment Corp ET AL increased its position in uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 1,371 shares during the period. Wells Fargo & Company MN lifted its position in shares of uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after purchasing an additional 1,503 shares during the period. Northern Trust Corp boosted its stake in shares of uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after purchasing an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in uniQure by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock worth $1,253,000 after buying an additional 3,996 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Stock Performance

Shares of uniQure stock traded down $0.46 during trading hours on Wednesday, reaching $15.04. 763,487 shares of the stock traded hands, compared to its average volume of 1,892,513. The company has a 50 day moving average price of $12.50 and a 200 day moving average price of $12.75. uniQure has a one year low of $3.73 and a one year high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $823.83 million, a price-to-earnings ratio of -3.03 and a beta of 0.10.

uniQure (NASDAQ:QURE - Get Free Report) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. On average, equities research analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research note on Monday, May 19th. Wells Fargo & Company cut their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Chardan Capital reaffirmed a "buy" rating and set a $38.00 target price on shares of uniQure in a research note on Monday, May 12th. Guggenheim restated a "buy" rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $37.82.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the transaction, the chief executive officer now owns 580,795 shares of the company's stock, valued at approximately $6,574,599.40. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 10,438 shares of uniQure stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares in the company, valued at approximately $2,240,441.70. This represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,762 shares of company stock valued at $521,973. 4.74% of the stock is owned by corporate insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.